In the trial, around 600 patients are expected to be enrolled who have failed prior systemic therapy.
Further, the patients will be given weekly intramuscular injections of ADI-PEG 20 until disease progression.
The Phase 3 trial which aims at over all survival, is a double-blind, randomized, placebo-controlled trial.
Polaris Medical Affairs executive vice president John Bomalaski said they believe ADI-PEG 20 is a cancer therapeutic not only for HCC, but also other arginine-dependent cancers such as leukemia, lymphoma, sarcoma and prostate cancer.
"We look forward to continuing clinical development in all of these areas to understand the full potential for this therapeutic," Bomalaski said.